Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 14/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13279458 | 0.87 | CCR9 (0.34) | NR1H2MEN1KMT2AMAPK1 | |
| SCHEMBL17907950 | 0.87 | MAPK1 (0.33) | NOTUMNR1H2BRD4NR1H3MAPK1 | |
| SCHEMBL17907924 | 0.85 | NR1H2 (0.35) | NR1H2MEN1KMT2ASIGMAR1MAPK1 | |
| SCHEMBL17907968 | 0.85 | HDAC1 (0.34) | NOTUMNR1H2MAPK1 | |
| SCHEMBL17907954 | 0.84 | NR1H2 (0.36) | NR1H2SIGMAR1MAPK1 | |
| SCHEMBL17907949 | 0.84 | GABRA1 (0.35) | MEN1KMT2AMAPK1 | |
| SCHEMBL17907981 | 0.83 | KDM4E (0.39) | NR1H2 | |
| SCHEMBL18229909 | 0.81 | NOTUM (0.46) | NOTUMSIGMAR1 | |
| SCHEMBL1770176 | 0.81 | KDM4E (0.34) | MAPK1 | |
| SCHEMBL17907922 | 0.81 | KCNQ3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20110112134-A1 | Tricyclic Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-7696222-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK FROSST CANADA LTD (CA) | 2010-04-13 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MERCK CANADA INC. (CA) | 2009-11-19 | — | — | US | disclosed |
| WO-2007019675-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2007-02-22 | — | — | WO | disclosed |
| US-5721245-A | ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0384349-B1 | Substituted pyrroles | HOFFMANN LA ROCHE (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072704-A1 | Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor | EGFR, ERBB2, ERBB4 | NOTUM 3245/4885NR1H2 2097/4885CA12 4771/4885 |
| US-20090286825-A1 | Indole derivatives as crth2 receptor antagonists | MC2R, HRH2, PTGDR | NOTUM 4041/4885NR1H2 77/4885CA12 2655/4885 |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | NOTUM 3876/4885NR1H2 4/4885CA12 2472/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | NOTUM 3644/4885NR1H2 1/4885CA12 3125/4885 |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | NOTUM 2272/4885NR1H2 1170/4885CA12 4548/4885 |
| US-20110112134-A1 | Tricyclic Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | NOTUM 1575/4885NR1H2 124/4885CA12 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.